Fulgent Genetics, Inc. Common Stock
FLGTFulgent Genetics, Inc. (FLGT) is a healthcare technology company specializing in genetic testing and related services. It provides comprehensive genetic testing solutions for healthcare providers, commercial partners, and consumers, leveraging advanced genomic analysis to assist in disease diagnosis, personalized medicine, and research. Founded in 2011, the company has evolved to become a significant player in the genetic testing industry, offering a wide array of tests in areas such as oncology, reproductive health, and rare diseases.
Company News
Fulgent Genetics reported Q2 earnings that exceeded analyst expectations, with revenue of $82 million, representing a 15% year-over-year increase, despite a 56% decrease in adjusted net income.
Law firm Bragar Eagel & Squire is investigating potential securities law violations by GoHealth, Semler Scientific, ADTRAN, and Fulgent Genetics, following DOJ investigations and financial reporting issues.
Law firm investigating potential securities law violations for four companies, including DOJ investigations and stock price declines related to alleged false claims and kickback schemes.
Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (FLGT) regarding potential false claims submitted under the Uninsured Program. The investigation follows Fulgent's disclosure in its annual report that it had received a civil investigative demand from the U.S. Department of Justice.
Bragar Eagel & Squire, P.C. is investigating potential claims against Semler Scientific Inc., ADTRAN Holdings, Inc., and Fulgent Genetics, Inc. regarding alleged violations of federal securities laws and/or other unlawful business practices.
